Report warns of critical time for pharma patents
A looming patent cliff facing major pharmaceutical companies is pushing the industry into a critical phase in terms of drug
innovation and consolidation, according to the latest annual life sciences research from IP law firm Marks & Clerk.
The rest of this document is only available to i-law.com online
If you are already a subscriber, please enter your details below to log in.